Treatment of metastatic breast cancer with vinorelbine and docetaxel

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 3, 2006, Pages 276-280

  Savio, Giuseppina ^a   Laudani, Agata ^a   Leonardi, Vita ^a   Pepe, Alessio ^a   Scianna, Caterina ^a   Gebbia, Vittorio ^b,c   Agostara, Biagio ^a  

^a Ospedale Oncologico M Ascoli   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c NONE   (Italy)

Author keywords

Docetaxel; Metastatic breast cancer; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOCETAXEL; NAVELBINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TAXOID; VINBLASTINE;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIARRHEA; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; TREATMENT OUTCOME; VOMITING; BREAST TUMOR; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; SURVIVAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 33744977872     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000215456.56584.fc     Document Type: Article

References (33)

1. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node positive breast cancer: the results of 20 year follow-up. N Engl J Med. 1995;332:901-906.
2. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer. 1978;41:1170-1178.
3. Clemons M, Lèahy M, Valle J, et al. Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes. Eur J Cancer. 1997;33:2171-2182.
4. Crown J. Non-anthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist. 2001;6(Suppl. 3):17-21.
5. Nabholtz JM. The role of taxanes in the management of breast cancer. Semin Oncol. 1999;26:1-3.
6. Van Oosterom AT. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer. Semin Oncol. 1995;22:22-28.
7. Fumoleau P, Delgado DM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol. 1993;11:1245-1252.
8. Gebbia V, Puozzo C. Oral versus intravenous vinorelbine: clinical safety profile. Expert Opinion Drug Safety. 2005;4:915-928.
9. Dieras V, Fumoleau P, Kalla S, et al. Docetaxel in combination with doxorubicin or vinorelbine. Eur J Cancer. 1997;33(Suppl. 7):S20-0-S22.
10. Aapro M. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer. Oncology (Willingston Park). 1997;11(Suppl. 8):46-49.
11. Hino M, Kobayashi K, Hayashihara K, et al. In vitro combination effect of docetaxel (RP56976) with vinca alkaloids on cancer cell line. Proc AACR. 1995;36:299 (abstr 1780).
12. Binet S, Fellous A, Lataste H, et al. In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence. Semin Oncol. 1989;16:5-8.
13. Aoe K, Ueoka H, Kiura K, et al. Synergistic effect of docetaxel and vinorelbine against in vitro growth of human small cell lung cancer line. Proc AACR. 1996;37:375 (abstr. 2560).
14. Campone M, Fumoleau P, Delecroix V, et al. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. Ann Oncol. 2001;12:909-918.
15. Fumoleau P, Fety R, Delecroix V, et al. Docetaxel combined with vinorelbine: phase I results and new study designs. Oncology (Willingston Park). 1997;11(Suppl. 6):29-31.
16. Ibrahim NK, Rahman Z, Valero V, et al. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. Cancer Invest. 2002;20:29-37.
17. Cattel L, Recalenda V, Airoldi M, et al. A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions. Farmaco. 2001;56:779-784.
18. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
20. Piccart MJ, Awada A. State-of-the-art chemotherapy for advanced breast cancer. Semin Oncol. 2000;27:3-12.
21. Geels P, Eisenhaur E, Bezjak A, et al. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol. 2000;18:2395-2405.
22. Miller VA, Krug LM, Ng KK, et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non small cell lung cancer. J Clin Oncol. 2000;18:1346-1350.
23. Kornek GV, Urlich-Pur H, Penz M, et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol. 2001;19:621-627.
24. Pectasides D, Dimopoulos MA, Aravantinos G, et al. First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study. Anticancer Res. 2001;21:3575-3580.
25. Marti JL, Bueso P, Mayordomo JI, et al. Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines. Ann Oncol. 2001;12:1061-1065.
26. Brugnatelli S, Riccardi A, Danova M, et al. Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: a phase II study. Oncol Rep. 2001;8:801-805.
27. Rodriguez J, Calvo E, Cortes J, et al. Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study. Breast Cancer Res Treat. 2002;76:47-56.
28. Andres R, Mayordomo JI, Isla D, et al. Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy. Br J Cancer. 2002;86:1017-1018.
29. Gomez-Bernal A, Cruz JJ, Garcia-Palomo, et al. Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study. Am J Clin Oncol. 2003;26:127-131.
30. Vassilomanolakis M, Koumakis G, Drufakou S, et al. Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemother Pharmacol. 2003;51:179-183.
31. Mayordomo JI, Milla A, Morales S, et al. Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer. Clin Breast Cancer. 2004;5:131-135.
32. Gomez-Bernal A, Cruz JJ, Garcia-Palomo, et al. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer. Anticancer Drugs. 2005;16:67-82.
33. Cals L, Nourygat P, Valenza B, et al. Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: a phase I/II study. Oncology. 2004;67:257-261.